Companion animals trial suggest that acalabrutinib is safe and exhibits activity in canine B-cell lymphoma patients and support the use of canine lymphoma as a relevant model for human non-Hodgkin lymphoma (NHL).

FDA approved for human use

Acalabrutinib

Demonstration of target inhibition in companion animal trial. Studies in dogs were used as a proof of target and refined measure of drug exposure.

Phase II human trial completed

Hydroxychloroquine

Validation of biomarker test for use in human trials; dose modulation. Companion animals trial demonstrated efficacy and surrogate endpoint.

FDA approved for human use

Ibrutinib

Proof-of-target for IND application; defined PK/PD relationship. Determined toxicity, biomarkers, and biologic activity

Phase III human trials

Ganetespib

PK, PD, efficacy and toxicity studies were conducted in companion animals naturally affected with malignant melanoma

Phase I human trials ongoing

NHS-IL12

Decision was made to not move forward with human studies based on companion animals trials results.

https://www.ncbi.nlm.nih.gov/books/NBK338437/

​

Human trials were not conducted

Sulphonamide PAC-1 or SPAC-1

Assessed single-agent activity and toxicity for development of tolerable dosing regimen.

Phase I human trials ongoing

PAC-1

Determined dosing regimen and supportive care protocols in companion animals. Identified adverse events, dose, and regimen.

Phase I human trials ongoing

KPT-335

Phase I study for lymphoma-bearing dogs to evaluate differential efficacy, pharmacodynamics, toxicology, and pharmacokinetics, supporting their further clinical development.

Phase I human trials ongoing

LMP400, LMP776 and LMP744

Studies in companion animals confirmed inhibition and tumor response. Important proof of concept study. Masitinib is EMA-approved for veterinary use.

Phase III human trials ongoing

Masitinib